Vincristin

DRUG5 trials

Conditions

Acute Lymphoid LeukemiaB-cell Non-Hodgkin LymphomaChemotherapeutic ToxicityDiffuse Large B-Cell LymphomaDiffuse Large B-cell LymphomaFollicular LymphomaGene AbnormalityMinimal Residual Disease

Phase 1

Phase Ib Study of Rocbrutinib in Combination with R-CHOP in Patients with Newly Diagnosed B-cell Non-Hodgkin Lymphoma

RecruitingNCT06251180

Guangzhou Lupeng Pharmaceutical Company LTD.B-cell Non-Hodgkin Lymphoma

Start: 2024-04-10End: 2029-12-31Target: 112Updated: 2025-03-25

R-CMOP in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma

RecruitingNCT06594640

Institute of Hematology & Blood Diseases Hospital, ChinaDiffuse Large B-cell Lymphoma

Start: 2024-05-30End: 2027-07-30Target: 108Updated: 2025-05-14

Phase 2

Multicentre Study to Determine the Cardiotoxicity of R-CHOP Compared to R-COMP in Patients With Diffuse Large B-Cell Lymphoma

CompletedNCT00575406

Arbeitsgemeinschaft medikamentoese TumortherapieDiffuse Large B-Cell Lymphoma

Start: 2007-12-31End: 2012-01-31Updated: 2013-08-30

Phase 3

Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5

RecruitingNCT06284122

The Lymphoma Academic Research OrganisationFollicular Lymphoma

Start: 2024-06-07End: 2034-04-30Target: 790Updated: 2024-10-15

Unknown Phase

Adult Acute Lymphoblastic Leukemia Treated With Pediatric Regimen in Brazil

RecruitingNCT05959720

Instituto do Cancer do Estado de São PauloAcute Lymphoid Leukemia, Chemotherapeutic Toxicity, Gene Abnormality +1

Start: 2023-09-05End: 2030-06-30Target: 180Updated: 2025-05-07

Related Papers

Rocbrutinib, a New-Generation BTK Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Non-GCB Diffuse Large B Cell Lymphoma

Blood2024-11-05

Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapies

Blood2024-10-2449 citations